This business is building a GPS for the nervous system. Would you invest? Comment below 👇

14 Dec 2023 · 1 min

Watch on YouTube

1:00

In a concise interview format, the founder of Autonomics Medical explains that the company is developing millimeter‑scale sensing technology embedded on a catheter to locate and treat problematic nerves with unprecedented precision. The current medical challenge is a lack of visibility into the nervous system, forcing doctors to treat patients without precise targeting. Autonomics Medical’s solution miniaturizes conventional sensors to a 1 × 2 mm microchip placed directly on a catheter, enabling real‑time nerve mapping. The business model envisions selling single‑use, insurance‑covered catheters to hospitals. The company is pre‑revenue, with zero sales this year as it prepares for clinical trials to validate efficacy. The long‑term vision is described as “building the GPS for the nervous system,” positioning the technology as a transformative diagnostic and therapeutic platform. The segment ends with an invitation for viewers to comment on whether they would invest.

What's the name of your business?
Autonomics Medical.
What is your business in one sentence?
We're developing sensing technology to be able to treat nerves right at the source with much greater precision than available on the market today.
What problem is your business solving?
We're solving the fact that doctors are currently having to treat patients without any visibility in the nervous system. And so our technology gives them the ability to see where problematic nerves are and treat them right at the spot.
What's your specific solution to the problem?
Our solution is to have taken typical sensing technology and bringing that down to the size of a 1 by 2 millimeter By taking a microchip and embedding it on a catheter, we can get right up next to the nerve in the body.
How do you make money?
We expect our technology is going to be covered by insurance, and so we'll sell single-use catheters to hospitals.
What will revenue be this year?
Zero, because we're a pre-revenue stage company still developing our technology and entering into clinical trials to demonstrate the efficacy of our technology.
What's the big vision?
We're building the GPS for the nervous system.
Comment below if you would invest in this business.